Abstract
Tafamidis is a transthyretin (TTR) stabilizer recently approved to slow the neurologic impairment in TTR familial amyloid polyneuropathy (TTR-FAP). The pivotal studies on Tafamidis reported encouraging results on the short term, in the early onset Val30Met-TTR-FAP patients at an early stage of the neuropathy. However, the effect of the drug in the non-Val30Met patients, at a more advanced stage of the disease and on the long term, is less known. In this study, we report the effect of Tafamidis in 43 TTR-FAP patients with a variety of pathogenic mutations, including 53% of non-Val30Met variants, at different stages of neuropathy followed on the long term. General and neurological assessment was performed in a standardized protocol every 6–12 months along with neurophysiological variables, including testing of small nerve fibres. The mean follow-up under treatment was 2 years with a subset of 26 patients treated for 3 years. Overall, Tafamidis was well tolerated. A significant clinical deterioration of the neuropathy and the patient’s general condition was observed across the 3 years follow-up, although neurophysiological parameters remained stable for the first 2 years. In contrast, patients had a significant increase of BMI under treatment. Deterioration of the neuropathy correlated to an older age at disease onset or treatment initiation and to poor clinical status at baseline. A higher BMI at baseline was associated with a lower progression of the neuropathy. About one-third of the patients who received 3 years of tafamidis had still preserved walking capacity or good clinical condition, suggesting that tafamidis slowed the disease progression in some patients. Overall, our work shows that tafamidis is well tolerated in TTR-FAP but does not prevent the steady progression of the neuropathy on the long term. Age, neurologic status, and general condition at baseline appear to be best predictors of tafamidis efficacy on the neurological function.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M et al (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66:2451–2466
Planté-Bordeneuve V, Said G (2011) Familial amyloid polyneuropathy. Lancet Neurol 10:1086–1097
Lefaucheur JP, Ng Wing Tin S, Kerschen P, Damy T, Planté-Bordeneuve V (2013) Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers. J Neurol 260:1497–1503
Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S et al (1991) Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 40:242–246
Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341:1113–1116
Benson MD (2013) Liver transplantation and transthyretin amyloidosis. Muscle Nerve 47:157–162
Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR et al (2015) Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99:1847–1854
Tasaki M, Ueda M, Obayashi K, Koike H, Kitagawa K, Ogi Y et al (2013) Effect of age and sex differences on wild-type transthyretin amyloid formation in familial amyloidotic polyneuropathy: a proteomic approach. Int J Cardiol 170:69–74
Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421:185–203
Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785–792
Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB et al (2013) Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802–2814
Lozeron P, Théaudin M, Mincheva Z, Ducot B, Lacroix C, Adams D et al (2013) Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol 20:1539–1545
Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S et al (2013) Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res 6:1011–1020
Dyck PJ, Davies JL, Litchy WJ, O’Brien PC (1997) Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49:229–239
Steen L, Ek B (1983) Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms. Acta Med Scand 214:387–397
Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220–2224
Lefaucheur JP, Wahab A, Planté-Bordeneuve V, Sène D, Ménard-Lefaucheur I, Rouie D et al (2015) Diagnosis of small fiber neuropathy: a comparative study of five neurophysiological tests. Neurophysiol Clin 45:445–455
Ng Wing Tin S, Planté-Bordeneuve V, Salhi H, Goujon C, Damy T, Lefaucheur JP (2015) Characterization of pain in familial amyloid polyneuropathy. J Pain 16:1106–1114
Mariani LL, Lozeron P, Théaudin M, Mincheva Z, Signate A, Ducot B et al (2015) French familial amyloid polyneuropathies network (CORNAMYL) study group. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901–916
Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y et al (2016) Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: a phase III, open-label study. J Neurol Sci 362:266–271
Cortese A, Vita G, Luigetti M, Russo M, Bisogni G, Sabatelli M et al (2016) Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. J Neurol 263:916–924
Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T et al (2013) Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 310:2658–2667
Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N et al (2015) Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology 85:675–682
Suanprasert N, Berk JL, Benson MD, Dyck PJ, Klein CJ, Gollob JA et al (2014) Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials. J Neurol Sci 344:121–128
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
Daniel Azoulay, Philippe Le Corvoisier, Cyrille Feray, Tarik Nordine, Jean Pascal Lefaucheur: None. Samar S. Ayache: travel grants or compensation from Genzyme, Biogen, Novartis, and Roche. Hayet Salhi: travel expenses from Pfizer, LFB. Farida Gorram: grants from Pfizer. Thibaud Damy: travel expense Pfizer; consultancy Alnylam, Ionis, Pfizer. Violaine Planté-Bordeneuve: travel expenses from Pfizer, Alnylam; Consultancy, Ionis, Pfizer; speaking fees from Pfizer, Prothena.
Ethical standards
The study was approved by our local Ethic commitee.
Rights and permissions
About this article
Cite this article
Planté-Bordeneuve, V., Gorram, F., Salhi, H. et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study. J Neurol 264, 268–276 (2017). https://doi.org/10.1007/s00415-016-8337-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-016-8337-3